POET’s $400 Million War Chest Arrives as Class Actions and a Lost Client Rattle the Stock

POET raised $400M for AI photonics expansion, but shares fell 22% as lawsuits, canceled Celestial AI order, and weak Q1 revenue hit sentiment.

POET Technologies has pulled in a whopping $400 million through a direct stock placement — a deal that gives it the financial firepower to supercharge its AI-focused photonics manufacturing. But the market greeted the news with a shrug, and the stock has been battered by a series of setbacks, including multiple class-action lawsuits and the abrupt cancellation of a major customer order.

The capital-raising closed on May 18, with a single institutional investor paying $21 per share for roughly 19 million new shares. The buyer also received warrants exercisable at $26.25 — a 25% premium to the issue price. The move is designed to fund a tenfold increase in production capacity by 2027, expand labs in Singapore, add assembly space in Malaysia, and pursue targeted acquisitions and research spending.

Yet the cash injection has done little to calm jittery shareholders. The stock fell 22% on Friday, then recovered 11% on Monday, only to slide further as fresh legal headaches emerged. Just days before the placement announcement, shares were trading above $20. By Monday’s close, they had slumped to $14.01 — a far cry from the placement price.

Legal woes are piling up. Multiple class-action suits accuse management of misrepresenting POET’s U.S. tax status, which could have adverse consequences for American investors. A more damaging allegation involves a leak by a senior executive that allegedly prompted Celestial AI — a Marvell subsidiary — to scrap all of its orders. When news of that leaked in late April, the stock cratered 45% in a single session. Investors have until June 29, 2026 to apply to lead the consolidated class action.

Operationally, the picture is mixed. POET recorded first-quarter revenue of just $500,000, far below the $2.2 million analysts had predicted. Operating expenses ballooned to over $18 million, driving a net loss of $0.08 per share — worse than the consensus forecast. CEO Suresh Venkatesan pointed to existing contracts as the engine of future growth, but the gap between heavy R&D spending and meager sales remains stark.

There are bright spots. A strategic supply agreement with Lumilens includes an initial order worth $50 million, with the relationship potentially expanding to half a billion dollars over time. And the company’s cash holdings now comfortably exceed its short-term liabilities, giving management the runway to ramp up its Asian production sites.

The C-suite is also in flux. CFO Thomas Mika has retired, while Sandeep Kumar takes on the role of chief operating officer. The leadership changes add to an already turbulent period, as short seller Night Market Research has attacked POET’s claims about partnership details, alleging exaggeration.

For all the headline noise, POET now has the financial resources to execute its vision. Whether it can navigate the legal storm, win back customer confidence, and narrow the gap between investment and revenue will determine if this high-stakes bet pays off.